Priapism Risk and ICI Safety: What Patients Should Know Before Starting Intracavernosal Injection Therapy
If your doctor has recommended intracavernosal injection (ICI) therapy for erectile dysfunction(ED), it is natural to have questions — and perhaps some concerns — about a treatment that sounds more confronting than a simple tablet.
Among those concerns, priapism stands out as the complication most commonly raised by patients. This article explains clearly what priapism is, how and why it can occur with ICI therapy, and what practical steps reduce that risk significantly so that you can make an informed decision alongside your physician.
- What intracavernosal injection (ICI) therapy is and how it works
- What priapism means, why it matters, and how commonly it occurs
- Which factors increase or reduce the risk
- How to respond if a prolonged erection does occur
- Who is and is not a suitable candidate for ICI therapy in Tokyo
Have a question about this treatment?
Message us on LINE or WhatsApp — our English-speaking team usually replies the same day.
What Is Intracavernosal Injection (ICI) Therapy?
Intracavernosal injection therapy is a well-established second-line treatment for erectile dysfunction (ED) in men who do not respond adequately to, or cannot tolerate, oral PDE5 inhibitors such as sildenafil (Viagra) or tadalafil (Cialis). The term “intracavernosal” simply means “into the corpora cavernosa” — the two sponge-like columns of erectile tissue that run the length of the penis.
A small-gauge needle is used to deliver vasoactive medication directly into this tissue, triggering smooth muscle relaxation and increased blood inflow, producing an erection that is largely independent of sexual arousal or psychological state.
The injection is performed by the patient at home after thorough in-clinic training, using a very fine needle comparable to those used in insulin self-injection. Most men describe the discomfort as minimal once they have practised the technique.
What medications are used?
The most common formulations are Bimix (a combination of papaverine and phentolamine) and Trimix (papaverine, phentolamine, and alprostadil). Alprostadil alone (available as a branded monotherapy) is also used. Each formulation and dosage is individualised: the starting dose is always determined in a supervised clinical setting, with the patient observed before any home use is permitted.
Understanding Priapism: What It Is and Why It Matters
Priapism is a prolonged erection that persists beyond four hours and is unrelated to sexual stimulation or desire.
The name derives from the Greek deity Priapus. Despite sounding like a trivial side effect, priapism is a genuine medical emergency when it is of the ischaemic (low-flow) type — meaning blood is trapped in the corpora cavernosa without adequate oxygenation. Left untreated, ischaemic priapism can cause permanent cavernous fibrosis and irreversible erectile dysfunction within 24–48 hours of onset.
It is important to distinguish ischaemic (veno-occlusive) priapism from non-ischaemic (high-flow, arterial) priapism. ICI-related priapism is almost always the ischaemic type. The affected tissue becomes increasingly hypoxic, acidotic, and eventually fibrotic if the erection is not resolved promptly. This is why patients are explicitly counselled on the four-hour rule before commencing home ICI therapy.
How common is ICI-related priapism?
Clinical reports indicate that the incidence of prolonged erection requiring medical intervention ranges from approximately 1% to 5% across published ICI series, with the wide variation reflecting differences in formulation, starting dose, and patient selection.
Studies suggest that Trimix, when properly dose-titrated in a clinical setting, carries a lower per-injection priapism rate than historical monotherapy alprostadil data, because the phentolamine and papaverine components allow lower individual doses of each agent.
A review published in the Journal of Sexual Medicine noted a clinically significant priapism rate of approximately 1–2% with supervised Trimix protocols, compared with rates closer to 3–5% in early unmonitored alprostadil programmes.
Dr. Karibe’s Note
A common question I receive at BIOTOPE CLINIC is whether priapism is inevitable with self-injection therapy.
The honest answer is that it is a real but manageable risk — one that disciplined dose titration and clear patient education reduce substantially. Many of our international patients are surprised to find that the initial supervised test dose session, where we observe the erectile response in clinic before allowing home use, is the single most important safety step. Skipping this step — whether by obtaining medication informally or adjusting doses without guidance — accounts for the majority of preventable cases I have seen.
Risk Factors and How to Reduce Them
Not every ICI patient carries the same level of priapism risk. Certain clinical and behavioural factors are consistently associated with higher incidence.
Factors that increase risk
- Sickle cell trait or disease — red blood cells sickle more readily in a low-oxygen, low-pH environment, exactly the conditions that develop in a sustained ischaemic erection.
- Haematological disorders — leukaemia, polycythaemia vera, and other conditions altering blood viscosity or coagulation.
- Concurrent use of anticoagulants or certain antidepressants — particularly trazodone, which has independent priapism associations.
- Dose escalation without physician oversight — self-adjusting the dose upward because previous doses “didn’t work well enough” is the most common behavioural trigger.
- Psychogenic ED patients — paradoxically, men with predominantly psychological rather than vascular ED may have exaggerated responses to even low ICI doses.
- Injection frequency — exceeding the recommended maximum of one injection per 24 hours and three per week is a well-documented risk multiplier.
Protective measures
- Always begin with a supervised in-clinic test dose session with observation for at least 60–90 minutes.
- Keep a reversal agent (phenylephrine for clinic use; see below) immediately accessible and understand the escalation pathway.
- Adhere strictly to prescribed dose and frequency limits.
- Report any erection lasting more than two hours to your treating physician — the four-hour threshold is the emergency trigger, but earlier contact is always better.
- Avoid combining ICI with PDE5 inhibitors on the same day unless explicitly directed by your physician.
What to Do If Priapism Occurs: A Clear Action Plan
Every patient starting ICI therapy should have a written action plan before performing the first home injection. The following framework is consistent with published urology guidelines.
| Time Since Erection Onset | Recommended Action | Setting |
|---|---|---|
| Under 2 hours | Vigorous physical exercise (climbing stairs, squats), application of ice pack to perineum — may resolve a mildly prolonged response | Home |
| 2–4 hours | Contact treating physician immediately; prepare to travel to emergency facility | Home / en route |
| Over 4 hours | Attend emergency department urgently — aspiration and/or intracavernosal phenylephrine injection required | Hospital emergency |
| Over 6 hours | Surgical shunting may be required; risk of permanent fibrosis increases substantially with each additional hour | Hospital (urology on call) |
In Japan, patients should be aware that not every emergency department physician will have immediate familiarity with priapism management. Bringing a short written clinical summary in Japanese — which your prescribing physician can provide — significantly accelerates appropriate care.
Who Is a Good Candidate for ICI Therapy — and Who Should Avoid It
Suitable candidates
- Men with confirmed organic ED (vascular, neurogenic, or post-surgical) who have trialled oral PDE5 inhibitors at therapeutic doses without adequate response
- Men for whom PDE5 inhibitors are contraindicated (e.g. nitrate medication users, certain cardiac conditions)
- Men who prefer a reliable, on-demand response not dependent on oral absorption timing
- Post-prostatectomy patients — ICI often remains effective when other options fail due to cavernous nerve disruption
Patients for whom ICI is generally not recommended
- Men with sickle cell disease or other priapism-predisposing haematological conditions
- Patients with severe coagulation disorders or on therapeutic anticoagulation
- Men with a history of prior priapism
- Patients with anatomical penile abnormalities (e.g. severe Peyronie’s disease with acute plaque) unless cleared by a urologist
- Patients lacking the manual dexterity or visual acuity to perform self-injection safely
In Dr. Karibe’s clinical experience at BIOTOPE CLINIC, a careful medical history review during the initial consultation identifies the large majority of higher-risk patients before any prescription is issued. Men’s health consultations at BIOTOPE include a thorough cardiovascular and pharmacological review to ensure ICI is contextually appropriate.
Common Misconceptions About ICI Therapy and Priapism
Misconception 1: “Priapism only affects younger men with a very strong response.”
In fact, priapism risk from ICI is dose-dependent and independent of age. Older men with vascular disease may have paradoxically high responses if their smooth muscle is highly sensitive to the vasodilatory agents used. The supervised dose-finding session is equally important for all age groups.
Misconception 2: “If I had no problem the first few times, I can adjust the dose myself.”
Dose tolerance with ICI is not linear. Therapeutic window, injection site variability, and concurrent lifestyle factors (alcohol, fatigue, medications) can all alter the erectile response to the same nominal dose. Dose adjustments must always be made with physician input — this is one of the most preventable causes of ICI-related priapism encountered in clinical practice.
ICI Therapy in Tokyo: Consultation and What to Expect
At BIOTOPE CLINIC in Shirokanedai, the men’s health service — offered exclusively at the BIOTOPE CLINIC location — provides English-speaking consultations for ED evaluation and ICI therapy under Dr. Karibe’s supervision.
The process begins with an initial consultation (¥3,300) and, if ICI therapy is considered, a dedicated surgical/specialist consultation with Dr. Karibe (¥2,200). Pre-treatment blood work (¥11,000) is standard to screen for contraindications. The supervised in-clinic test dose session, dose titration, and patient education are conducted before any home prescription is issued.
For patients who do not yet require injection therapy, BIOTOPE CLINIC also offers oral PDE5 inhibitor prescriptions (sildenafil, tadalafil) as a first-line approach. ICI therapy with Trimix or Bimix is available for those who progress to second-line treatment. For an accurate quote tailored to your specific situation, a consultation is recommended.
Have a question about this treatment?
Message us on LINE or WhatsApp — our English-speaking team usually replies the same day.
Where to Receive ICI Therapy in Tokyo
Within our clinic group, English-speaking consultations are handled at BIOTOPE CLINIC in Shirokanedai (Minato-ku, Tokyo) by Dr. Jun Karibe. Our sister clinic, Kojimachi Dermatology & Plastic Surgery Clinic in Ichigaya (Chiyoda-ku), is the group’s main office and handles Japanese-language insurance-covered dermatology — it is not currently set up for English-language consultations. All English enquiries — including men’s health, ICI therapy, and ED consultations — should be directed to BIOTOPE CLINIC via LINE or WhatsApp.
Frequently Asked Questions
- Q. How long does the supervised test dose session take at the clinic?
- The session typically requires 90 minutes to two hours in total. After the injection is administered by the physician, the patient is observed in clinic for at least 60–90 minutes to assess the erectile response, confirm resolution, and adjust the prescribed home dose accordingly. Patients should not plan to drive themselves home on the same day.
- Q. Can I combine my ICI dose with a PDE5 inhibitor tablet on the same day?
- This combination significantly amplifies the vasodilatory effect and substantially increases priapism risk. It should not be done without explicit written instruction from your physician. The two approaches are generally prescribed as alternatives rather than simultaneous treatments.
- Q. What is the reversal agent for ICI-induced priapism and is it available in Japan?
- Phenylephrine, injected intracavernosally by a healthcare provider, is the standard first-line reversal agent recommended in international urology guidelines. It is available in Japanese hospital settings, though patients should arrive at an emergency department promptly rather than waiting. Adrenaline (epinephrine) is used as a substitute in some facilities. Bringing a Japanese-language clinical summary from your prescribing physician ensures the ER team understands the presentation immediately.
- Q. Does having ICI-related priapism once mean I have to stop treatment permanently?
- Not necessarily, but it does require a thorough review with your physician before resuming. In many cases, dose reduction resolves the issue and safe continuation is possible. However, men with recurrent priapism events or an identified haematological predisposition may need to discontinue ICI and consider alternative treatments.
- Q. Are consultations at BIOTOPE CLINIC conducted in English?
- Yes. English-speaking doctor consultations are currently available at BIOTOPE CLINIC in Shirokanedai, conducted by Dr. Jun Karibe. The clinic’s English-speaking support team also handles enquiries via LINE and WhatsApp. The group’s sister clinic, Kojimachi Dermatology & Plastic Surgery Clinic in Ichigaya, operates in Japanese only.
Have a question about this treatment?
Message us on LINE or WhatsApp — our English-speaking team usually replies the same day.
Summary
ICI therapy with Trimix or Bimix is a reliable, evidence-supported treatment for men whose erectile dysfunction has not responded adequately to oral medication.
Priapism is its most significant safety concern — a genuine medical emergency if it exceeds four hours — but clinical reports indicate that with proper dose titration, supervised initiation, and clear patient education, the risk can be reduced to the 1–2% range in well-managed programmes.
The essential safeguards are straightforward: begin with a supervised in-clinic test dose, never self-adjust the prescribed dose, respect frequency limits, and know precisely what to do if an erection lasts longer than two hours.
Men with sickle cell disease, significant haematological disorders, or a prior history of priapism require particularly careful evaluation before ICI therapy is considered.
If you have questions about priapism risk, ICI therapy, or ED treatment in general, English-speaking consultations are handled at BIOTOPE CLINIC in Shirokanedai (Minato-ku, Tokyo) by Dr. Karibe. Our sister clinic Kojimachi Dermatology & Plastic Surgery Clinic in Ichigaya (Chiyoda-ku) handles Japanese-language insurance dermatology. English enquiries: LINE or WhatsApp.
24/7 Consultation & Booking
Book a Consultation or Treatment
Our English-speaking team responds via LINE or WhatsApp — usually the same day.
References
- Burnett AL, Sharlip ID. Standard operating procedures for priapism. Journal of Sexual Medicine. 2013.
- Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. Journal of Urology. 2003.
- Porst H, Buvat J, eds. Standard Practice in Sexual Medicine. Blackwell Publishing. 2006.
- Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urologic Clinics of North America. 2001.
- Gross MS, Broghammer JA, Kaufman MR, et al. Intracavernosal injection therapy: a review of efficacy and adverse events in the era of pharmacological erectogenic agents. Sexual Medicine Reviews. 2019.
SUPERVISED BY
Dr. Jun Karibe
MD
Director
Education & Career
Certifications
Awards
